Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2011-06-21
2011-06-21
Solola, Taofiq A (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S139000
Reexamination Certificate
active
07964645
ABSTRACT:
The present invention relates to compounds of formula IwhereinR1,R2, R3,R4,R5, X, and n are as defined herein and the dotted line denotes an optional bond and pharmaceutically acceptable acid addition salts thereof. The compounds are useful in the treatment of neurological and neuropsychiatric disorders.
REFERENCES:
patent: 6506782 (2003-01-01), Thorsett
patent: 0838471 (1998-04-01), None
patent: WO 99/55688 (1991-11-01), None
patent: WO 96/33161 (1996-10-01), None
patent: WO 98/22433 (1998-05-01), None
patent: WO 99/34790 (1999-07-01), None
patent: WO 2006/080477 (2006-08-01), None
Pacic et al., J. Med. Chem. (2005), vol. 48(2), pp. 475-482; Connor et al.
Frank et al., Pept. Proc. Am. Pept. Symp., 5th, (1977), pp. 514-517.
Lewis D.A. & Lieberman J.A., Neuron. vol. 28, pp. 325-334 (2000).
Vandenberg R. J. & Aubrey K. R., Exp. Opin. Ther. Targets vol. 5(4) pp. 507-518 (2001).
Nakazato A. & Okuyama S., Exp. Opin. Ther. Patents vol. 10(1) pp. 75-98 (2000).
Sharma T., Br. J. Psychiatry, vol. 174 (Suppl. 38) pp. 44-51 (1999).
Javitt D. C. et al., Biol. Psychiatry, vol. 45 pp. 668-679 (1999).
Mohn A. R., Cell vol. 98 pp. 427-436 (1999).
Bliss, T. V. & Collingridge G. L., Nature, vol. 361 pp. 31-39 (1993).
Tang J. P. et al., Nature, vol. 401, pp. 63-69 (1999).
Gainetdinov R. R. et al., Trends in Pharm. Sci. vol. 23(8) pp. 367-373 (2002).
Lopez-Corcuera B, et al., Mol. Mem. Biol. vol. 18 pp. 13-20 (2001).
Bergeron R. et al., Proc. Natl. Acad. Sci. USA vol. 95, pp. 15730-15734 (1998).
Chen et al., J. Neurophysiol. vol. 89(2) pp. 691-703 (2003).
Pralong, et al., Prog. Neurobiol. 67, pp. 173-202 (2002).
Carlsson M. L., J. Neural Transm. 105, pp. 525-535 (1998).
Armer et al., Exp. Opin. Ther. Patents 11(4) pp. 563-572 (2001).
Baruah et al., Synlett pp. 409-410 (1999).
Laurent et al., Synthesis pp. 667-672 (2000).
Dejaegher et al., Synlett, 1, pp. 113-115 (2002).
Sakaiubara et al., Bulletin of the Chem. Society of Japan vol. 40, No. 9, pp. 2164-2167 (1967).
Steglich et al., Abstract XP-002458221, Pept. Proc. Eur. Pept. Symp. 8thMeeting (1967), pp. 67-72.
Ooi, et al., J. Am. Chem. Soc. vol. 127, No. 14, pp. 5073-5083 (2005).
Conley et al., J. Med. Chem. vol. 30, pp. 567-574 (1987).
Rajic et al., Molecules, vol. 11, No. 11, pp. 837-848 (2006).
Abstract XP-002458222: Enamine Screening Library (2007).
Jolidon Synese
Narquizian Robert
Pinard Emmanuel
Hoffmann-La Roche Inc.
Johnston George W.
Prior Kimberly J.
Rocha-Tramaloni Patricia S.
Solola Taofiq A
LandOfFree
Di-aromatic substituted amides as inhibitors for GlyT-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Di-aromatic substituted amides as inhibitors for GlyT-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Di-aromatic substituted amides as inhibitors for GlyT-1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2745665